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Summary 
 
The International Federation of Gynecology and Obstetrics (FIGO) has identified non 
communicable maternal diseases  (NCDs) as a new focus area.  NCDs and exposures as 
related to pregnancy complications and later impairment of maternal and offspring health will 
form the basis for action in the forthcoming years.  
This paper summarizes recent advances, centered on the use of first-trimester testing, as a 
window of opportunity to predict and prevent many pregnancy complications; and for 
potential future prevention of NCDs in mother and offspring. Recent results from a large-
scale randomized control trial have provided definitive proof that effective screening for 
preterm preeclampsia (preterm-PE), requiring delivery before 37 weeks’ gestation, can be 
achieved with a combined test of maternal factors and biomarkers at 11-13 weeks and that 
aspirin, given to high-risk women, is effective in reducing the risk of preterm-PE and the 
length of stay in neonatal intensive care unit. This is the first successful example to illustrate 
that pregnancy complications is predictable and preventable in early pregnancy. Similar 
prediction and prevention strategies are being developed for hyperglycemia in pregnancy and 
preterm birth, with the intention for longer lasting interventions leading to significant 
downstream impact in improving long-term health in both mothers and babies. 
Keywords: First-trimester; Prediction; Prevention; Non-communicable diseases; Pregnancy 
complications; Preeclampsia; Hyperglycemia; Gestational diabetes; Preterm birth 
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Introduction 
The International Federation of Gynecology and Obstetrics (FIGO) has identified non 
communicable maternal diseases  (NCDs) as a new focus area.  NCDs and exposures as 
related  to pregnancy complications and to later impairment of maternal and offspring health  
(including maternal overweight and obesity, hyperglycemia, hypertension,  malnutrition, 
anemia, thyroid disorders, environmental pollution, smoke exposure (household, 
environmental and tobacco smoking), gender violence and mental health) will form the basis 
for action in the forthcoming years.  
 
Pregnancy is the center of this program with specific timepoints for intervention identified as:  
• Pre-pregnancy (women already affected by NCD) 
• Pregnancy – as early as possible but focusing on the first-trimester  
• Post-pregnancy for both mother and offspring, leading towards prevention of NCD  
 
In pragmatic terms, the first-trimester visit provides the most accessible platform for early 
identification of many pregnancy complications and for potential future prevention of NCDs 
in mother and offspring.   
 
This paper summarizes recent advances, centered on the use of first-trimester testing, as a 
window of opportunity to predict and prevent multiple pregnancy complications.  Such 
testing also provides the opportunity for longer lasting interventions, with significant 
downstream impact in improving long-term health in both mothers and babies. 
 
NCDs impact maternal health 
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Declaration of the World Health Organization (WHO) Millennium Development Goals 
(MDGs 3, 4 and 5) [1] resulted in justifiable attention on maternal and child health (MCH) 
programs, especially in the developing world. 
 
MCH programs had previously focused on factors that directly and immediately impacted 
maternal, neonatal and infant mortality, resulting in improved access to maternity services 
and improved survival of ‘at-risk’ mothers and their offspring in many low and middle-
income countries. Unfortunately, this narrow short-term focus failed to address the root 
causes and social determinants of health, and the very individuals saved continue to be 
vulnerable and are at the highest risk of NCDs later in life.  
 
Undernutrition, overweight and obesity; hypertension; hyperglycemia and other 
complications are commonly associated with pregnancy and cause considerable maternal 
morbidity and mortality, poor pregnancy outcomes as well as adverse fetal programming. To 
improve both short-term MCH outcomes and long-term population health, NCDs must be 
addressed simultaneously with immediate MCH.  
 
Worldwide, one in six pregnancies may be associated with hyperglycemia, with 84% of cases 
involving gestational diabetes (GDM) and 16% overt diabetes in pregnancy. In 2013, 16.8% 
live births (21.4 million) were associated with hyperglycemia in pregnancy (HIP).  
 
Apart from pregnancy complications and poor outcomes, HIP increases later health risks for 
mother and offspring and is the most reliable marker of future type 2 diabetes mellitus 
(T2DM) and cardio-metabolic disorders in women. Offspring of mothers with HIP have a 
heightened risk of early onset overweight, obesity, insulin resistance, pre-diabetes, T2DM 
and cardio-metabolic disorders as a consequence of adverse intrauterine developmental 
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programming. This makes female offspring of mothers with HIP highly vulnerable to 
hyperglycemia during pregnancy as well as polycystic ovarian syndrome (PCOS). 
  
Worldwide, high blood pressure with or without proteinuria is a major cause of maternal 
morbidity and mortality, with hypertensive pregnancy disorders (HPD) accounting for 10% 
and 15% of maternal deaths in low-/middle-income countries respectively.  HDP also 
contribute to increased perinatal morbidity and mortality as a consequence of prematurity and 
poor fetal growth.  
 
Although the incidence varies in different parts of the world, overall nearly 10% of 
normotensive women experience hypertension at some point during pregnancy. 
Preeclampsia/eclampsia have the highest impact on mortality and morbidity, including renal 
or liver failure, clotting disorders, stroke, preterm delivery, stillbirth or neonatal death and  
(especially emergency) Cesarean section. Women with previous HPD manifest higher 
glucose, insulin, triglycerides and total cholesterol levels after pregnancy. Women with HPD 
carry a lifetime increased risk of cardiovascular and metabolic disorders, including a twofold 
increased risk of hypertension, a threefold increased risk of T2DM and increased risk of 
dyslipidemia. Offspring of mothers with preeclampsia (PE) have higher blood pressure 
during childhood and young adulthood.  
 
Maternal health impacts future burden of NCDs 
Prenatal and early-life development influences the risks of NCDs in later life through 
epigenetic changes, and this may be especially relevant in low-resource countries. The 
parents' health, particularly the mother's body composition, nutritional, metabolic and 
psychological status during pregnancy, determines the fetal environment and impacts the risk 
of later NCDs. Ensuring a healthy pregnancy and a disease-free early childhood may be the 
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most effective means of attaining best future health and preventing NCDs. The fetal 
environment represented by the mother's peri-conceptional and gestational health determines 
whether one starts life with a health ‘advantage’ or ‘handicap’. It is on this ‘foundation’ that 
NCD risk factors play out in later life.  
 
Developmental effects operate through a gamut of subtle influences which provide the fetus 
the cues (via the intrauterine environment) to predict the external environment it will be born 
into, as well as the flexibility to adjust its growth trajectory to match that environment. The 
concept of fetal programming and its consequences are paradigm changing. It highlights that 
pregnancy offers a window of opportunity to provide maternal care services, not only to 
reduce the traditional short-term maternal and perinatal morbidity and mortality indicators 
but also for intergenerational prevention of several chronic diseases.  
 
The UN Sustainable Development Goals highlight multiple issues which are important social 
determinants of health such as poverty, hunger, education, gender equality, water and 
sanitation, clean energy and pollution; and promote integrated action on health to address 
maternal and child health. They aim to reduce both NCDs and common infectious diseases, 
providing a unique platform to address the links between maternal and child health and NCD 
prevention and care.    
 
FIGO's Focus on NCDs 
Since 1954 FIGO has been the only global organization representing national societies of 
obstetricians and gynecologists. FIGO now has Member Societies in 130 countries or 
territories. FIGO's vision is that women of the world achieve the highest possible standards of 
physical, mental, reproductive and sexual health and wellbeing throughout their lives. FIGO's 
work is dedicated to the improvement of women’s health and rights and to the reduction of 
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disparities in healthcare available to women and newborns, as well as to advancing the 
science and practice of obstetrics and gynecology. 
 
Realizing the increasing relevance of NCDs in maternal and offspring health, FIGO has 
recently established a committee on Pregnancy and NCD to emphasize on the centrality of 
the health, nutrition and behavior of girls, adolescents and young women of reproductive age 
(and, where appropriate, their partners) not only to improve pregnancy outcomes but also as 
the most effective and sustainable way to address the prevention of NCDs and build the 
foundation for better population health in the next generation.   
 
The key focus areas of the committee will include Prediction and Prevention of Pregnancy 
Complications as a consequence of common NCDs and the Life Course Approach to NCD 
Prevention.  Pregnancy, in particular the first trimester, will receive substantial attention but 
other crucial points of intervention – e.g. pre-conception and postpartum also rate as high 
priorities. 
 
While all areas will require a public health, awareness and advocacy approach, in some areas 
a more focussed clinical or basic science approach will be required, including the 
development of guidelines and clinical practice recommendations. When possible and 
feasible, synergistic interaction with programs related to maternal communicable diseases 
such as HIV, malaria or tuberculosis with significant impact on pregnancy outcome and fetal 
development will be considered, but these will not be the primary focus of this committee.  
 
The FIGO Pregnancy and NCD committee will also promote awareness and action on other 
components of the life course prevention of NCD risk such as teenage pregnancy and access 
to contraception, girls’ education, interpregnancy interval and breastfeeding support. 
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Specific focus areas 
(1) Preeclampsia  
Preeclampsia (PE) is a multisystem disorder of pregnancy classically characterized with the 
onset of hypertension after 20 weeks’ gestation in the presence of proteinuria. PE typically 
affects 2-5% of pregnant women [2] and it is one of the leading causes of maternal and 
perinatal mortality and morbidity. It has been estimated that 75,000 maternal deaths 
worldwide are attributed to hypertensive disorders in pregnancy [3]. PE can be further 
classified into preterm-PE, where delivery is required at <37 weeks’ gestation and term-PE, 
with delivery at >37 weeks’ gestation. It is preterm-PE, rather than term disease, that is 
associated with a substantial risk of short- and long-term maternal and perinatal morbidity 
and mortality [4-8].  
Prediction of preeclampsia 
An effective screening tool is essential to guide clinicians to correctly identify women at 
high-risk of developing PE. This subsequently allows early introduction of prophylactic 
treatment and therapeutic intervention and increased surveillance of such pregnancies. 
Currently, the National Institute for Health and Clinical Excellence (NICE), in the United 
Kingdom, recommends that women at high-risk of PE should take 75 mg of aspirin daily 
from 12 weeks until the birth of the baby. Women are considered to be at high-risk of 
developing PE if they have any one high-risk factor or any two moderate-risk factors.  The 
high-risk factors are history of hypertensive disease in previous pregnancy, chronic kidney 
disease, autoimmune disease, diabetes mellitus or chronic hypertension; and the moderate-
risk factors are first pregnancy, age >40 years, inter-pregnancy interval >10 years, body mass 
index at first visit of >35 kg/m2 or family history of PE [9]. In the United States, according to 
the American Congress of Obstetricians and Gynecologists (ACOG) women are at high-risk 
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of developing PE if they fulfill any of the following factors: PE in previous pregnancy, 
chronic hypertension, chronic renal disease, diabetes mellitus, systemic lupus erythematosus 
or thrombophilia, nulliparity, age >40 years, BMI >30 kg/m2, family history of PE, or 
conception by in vitro fertilization [10]. Both recommendations essentially treat each risk 
factor as a separate screening test with additive detection rate and screen positive rate. 
 
An alternative approach to screening, developed by the Fetal Medicine Foundation (FMF), 
allows estimation of individual patient-specific risks of PE requiring delivery before a 
specified gestational age. The approach uses Bayes theorem to combine the a priori risk from 
maternal factors, derived by a multivariate logistic model, with the results of various 
combinations of biophysical and biochemical measurements [11,12]. In a previous study, 
data from prospective screening in 35,948 singleton pregnancies at 11-13 weeks’ gestation 
were used to develop an algorithm for the calculation of patient-specific risk of PE [12]. 
Combined screening by maternal factors, mean arterial pressure (MAP), uterine artery 
pulsatility index (UTPI), serum placental growth factor (PLGF) and serum pregnancy 
associated plasma protein-A (PAPP-A) achieved detection rates of preterm-PE and term-PE 
of 75% and 47%, respectively, at false positive rate of 10%. This prediction algorithm has 
now been validated prospectively in several studies [13-15].  
 
Prevention of preeclampsia 
There is now substantial evidence from the ASPRE trial (www.aspre.eu) that the rate of 
delivery with preterm-PE can be reduced by >60% by aspirin started at 11-14 weeks’ 
gestation in high-risk women [16]. The ASPRE trial was designed to test the hypothesis that 
aspirin at a dose of 150 mg per night from 11-14 until 36 weeks’ gestation, as compared with 
placebo, would result in halving the incidence of preterm-PE. In this multicenter, double-
blind, placebo-controlled trial, women with singleton pregnancies identified as being at high-
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risk of preterm-PE, by means of the first-trimester combined test were randomized to receive 
aspirin (150 mg per night) vs. placebo from 11-14 until 36 weeks’ gestation. Preterm-PE 
occurred in 1.6% (13/798) participants in the aspirin group, as compared with 4.3% (35/822) 
in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20-
0.74). However, there was no significant reduction in the rate of term-PE with the use of 
aspirin prophylaxis (odds ratio in the aspirin group, 0.95; 95% confidence interval, 0.57-
1.57). Adherence was good, with reported intake of >85% of the required number of tablets 
in 80% of participants. There were no significant between-group differences in adverse 
events.  
 
A secondary analysis of data of 1,620 participants with 1,571 liveborn neonates showed that 
the total length of stay in neonatal intensive care (NICU) was substantially longer in the 
placebo than aspirin group (1,696 vs. 531 days). This was a reflection of significantly shorter 
mean lengths of stay in babies admitted to the NICU from the aspirin than the placebo group 
(11.1 vs. 31.4 days; a reduction of 20.3 days) [17]. Neonatal intensive care of babies born at 
<32 weeks’ gestation contributed 1,856 (83.3%) of the total of 2,227 days in NICU across 
both treatment arms. These occurred in 9 (1.2%) of the 777 livebirths in the aspirin group and 
in 23 (2.9%) of 794 in the placebo group (odds ratio 0.42). Overall, in the whole population, 
including zero lengths of stay for those that were not admitted to the NICU, the mean length 
of stay was longer in the placebo than aspirin group (2.06 vs 0.66 days; reduction of 1.4 days. 
This corresponded to a reduction in length of stay of 68% [17]. 
 
Results from the ASPRE trial are definitive proof that effective screening for preterm-PE can 
be achieved with a combined test of maternal factors and biomarkers at 11-13 weeks and that 
high-risk women can take aspirin at 150 mg per night from the first trimester of pregnancy to 
significantly reduce their chances of developing preterm-PE. Furthermore, in pregnancies at 
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high-risk of preterm-PE, administration of aspirin reduces the length of stay in the NICU by 
about 70%. The findings have implications for both short- and long-term healthcare costs as 
well as infant survival and disability. 
 
This is the first successful example to illustrate that pregnancy complications is predictable 
and preventable in early pregnancy.  
 
(2) Preterm birth  
Preterm birth (PTB) defined as delivery before 37 completed weeks (<259 days) is the 
leading cause of perinatal death and disability in children and the vast majority of mortality 
and morbidity relates to early delivery before 34 weeks’ gestation, which occurs in about 2% 
of singleton pregnancies worldwide. In a multicenter study of survivors born before 26 
weeks’ gestation, 80% were disabled at the age of 6 years [18]. The economic burden of 
prematurity relates not only to the initial neonatal intensive care but also the longer-term 
increased use of medical, social and specialist educational services, as well as the lost 
economic productivity. In the United States the cost of PTB is estimated to be $26 billion per 
year [19]. 
 
Prediction of spontaneous preterm birth 
PTB occurs due to spontaneous onset of labor or preterm prelabor rupture of membranes in 
two-thirds of cases. In the other one-third it is medically indicated, mainly due to PE and/or 
fetal growth restriction (FGR), which are now predictable in early pregnancy. 
 
The most widely adopted approach to identifying pregnancies at high-risk of spontaneous 
preterm birth (sPTB) is based on a prior history of preterm delivery. There is substantial 
evidence supporting the sonographic measurement of cervical length (CL) as a reliable 
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screening test for sPTB at midtrimester [20-24], but there are still contradictory reports about 
the value of such screening at the first-trimester of pregnancy. Two groups have found a 
shorter CL at 11-13 weeks’ gestation in women who subsequently have early sPTB [25,26]. 
In a prospective screening study including approximately 10,000 singleton pregnant women 
who attended for a first-trimester scan for nuchal translucency measurement, the authors 
concluded that the median CL by multiple of median approach was significantly lower in 
both the early (<34 wks) and late sPTB groups compared to the term delivery group. They 
also reported that an algorithm combining maternal characteristics and CL could identify 
approximately 55% of those delivering preterm with a false-positive rate of 10% [25]. 
Moreover, Souka et al., in a prospective study of 978 singleton pregnancies scanned at the 
first-trimester, also concluded that the CL was significantly shorter in pregnancies that 
delivered before 34 weeks [26]. However, others studies, with smaller samples, have not 
demonstrated such capability for the CL performed in the first-trimester [27-29], although 
one of the studies observed that cervical shortening from the first to the second-trimester had 
a relationship with PTB [28]. Once effacement begins at the internal cervical os and 
progresses caudally [20,30], it is often detected on ultrasound examination before it can be 
appreciated on physical examination, therefore, the first-trimester scan could detect a shorter 
cervix before any physical examination [30]. 
 
Although the reason for these contradictory results is not clear, we can hypothesize regarding 
some explanations. Firstly, there might be some technical considerations with regard to 
differences in the methodology used for the first-trimester CL assessment between some 
studies, therefore it is crucial to follow a standardized methodology; secondly, the ethnicity 
differs between studies and thirdly there are other factors, which are also associated with an 
increased rate of sPTB and short cervix, that have not been evaluated in these studies, such as 
sociodemographic characteristics and psychosocial status [31,32]. 
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In light of these studies, a two-step approach to screening is preferred: (a) in the first-
trimester, perform CL assessment by transvaginal scan which also allows detailed 
morphological evaluation of the fetus; and (b) repeat the measurement of the CL during the 
anomaly scan at 20-24 weeks; for those with a cervix >25 mm, no addition prevention 
strategy will be needed, and for those with a short cervix (<25 mm), the subsequent 
management would take into account the prior history of sPTB.  
The implementation of such combined screening model within routine prenatal care has the 
potential to make a significant impact on the identification of the high-risk group for sPTB. 
Nevertheless, larger studies involving several thousands of pregnancies will define the exact 
relation between the CL at 11-13 weeks and the risk of sPTB; and the performance of such 
early screening either by CL alone or in combination with maternal characteristics, 
biomarkers and metabolomics. Similarly, the extent to which early identification of the group 
at high-risk of subsequent early delivery would improve pregnancy outcome through earlier 
intervention remains to be determined. 
 
Professional recommendations 
The International Federation of Gynecology and Obstetrics (FIGO) recommends 
sonographic CL screening in all women 19 to 23+6 weeks’ gestation using transvaginal 
ultrasound [33]. Women with a CL ≤25 mm should be treated with daily vaginal 
progesterone. 
 
The Society for Maternal-Fetal Medicine (SMFM) recommends routine transvaginal 
ultrasound CL screening between 16 and 24 weeks’ gestation for women with a singleton 
pregnancy and prior history sPTB [34]. They consider screening reasonable for women with 
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a singleton pregnancy and no history of prior sPTB but have not recommended routine 
screening for this population.  
 
Although, the American College of Obstetricians and Gynecologists (ACOG) neither 
mandated universal routine CL screening in women without a prior preterm birth nor 
recommended against such screening in its Practice Bulletin on preterm birth, the ACOG 
considered it and recommended that the cervix be examined when technically feasible in 
women undergoing obstetrical ultrasound examination [35,36]. 
 
Prevention of spontaneous preterm birth 
There is substantial evidence showing that vaginal progesterone significantly decreases the 
risk of preterm birth ≤34 weeks by 34% among women with prior history of preterm delivery 
and/or a midtrimester CL ≤25 mm. Furthermore, pooled estimates obtained by combining 
data from four trials indicate that vaginal progesterone was associated with a statistically 
significant reduction in the risk of preterm birth from <28 to <36 weeks’ gestation, 
respiratory distress syndrome, composite neonatal morbidity and mortality, birthweight 
<1500 g, and admission to NICU. Vaginal progesterone is safe and had no effect on the risk 
of both fetal death [37] and on the risk of adverse neurodevelopmental outcomes. There were 
no significant differences in the cognitive composite scores or rates of neurodevelopmental 
impairment up to six years of age between children exposed in utero to vaginal progesterone 
and those exposed to placebo [37-41]. 
 
Cervical cerclage does not appear to be effective for women with a short cervix who have not 
had a prior preterm birth [42]. In a meta-analysis of four randomized trials in which singleton 
pregnancies were screened with cervical ultrasound examination and randomly assigned to 
cerclage or no cerclage if the cervix was short, cerclage placement in women with no prior 
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preterm birth did not result in significant reduction in birth <35 weeks (21% vs 31% without 
cerclage: relative risk 0.84, 95% CI 0.60-1.17) [42]. In women with a short cervix (≤25 mm) 
at midtrimester, singleton gestation and prior preterm birth earlier than 34 weeks, cerclage 
and vaginal progesterone are equally effective in an indirect comparison meta-analysis for 
preventing preterm birth and improving perinatal outcomes [43]. However, the choice of 
treatment should depend on the risk of adverse events and cost-effectiveness of interventions, 
and patient/physician’s preferences. 
 
Use of a pessary in women with a short CL has been proposed as an effective, inexpensive, 
and easy-to-implement method for prolonging pregnancy. Efficacy is not supported by the 
body of literature.  Although some trials have reported a reduction in births <34 weeks’ 
gestation, others have not find such reduction. 
 
Finally, the implementation of a combined screening model within routine prenatal care in 
the first-trimester and the use of prophylactic progesterone in pregnancies at the highest risk 
of sPTB or cerclage for those with prior history and short cervix has the potential to make a 
significant impact on the rate of sPTB and its associated mortality and morbidity. 
Nevertheless, this approach needs to be tested in a large randomized control trial (RCT) to 
confirm the findings in the smaller studies. In fact, at the moment, we strongly advice those 
who perform CL screening to follow reliable standardized methodologies such as those from 
the Cervical Length Education and Review program (CLEAR) and the FMF 
(www.fetalmedicine.org).  
 
(3) Hyperglycemia in Pregnancy  / Gestational diabetes  
Gestational diabetes (GDM) is defined as carbohydrate intolerance, demonstrated by the 
presence of hyperglycemia, that is first recognized during pregnancy [44]. In the third 
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trimester of pregnancy, increased maternal blood glucose levels are associated with adverse 
maternal and neonatal pregnancy outcomes including PE, Cesarean section, macrosomia, 
shoulder dystocia and neonatal hypoglycemia, hyperbilirubinemia and cardiomyopathy 
[45,46]. GDM also impacts long-term health outcomes of both mothers and their babies – 
consequences that are discussed in more detail below. Treatment during pregnancy can 
improve perinatal outcomes [47,48]. 
 
The diagnosis of GDM is typically made by presenting the mother with a glucose challenge 
at 24-28 weeks’ gestation. A number of diagnostic criteria have been applied, which can 
complicate comparison of research data. Whilst the choice of diagnostic criteria remains 
controversial there appears to be some consensus in moving to the diagnostic criteria recently 
promoted by IADPSG [49,50]. The prevalence of GDM is approximately 15% - making this 
the most common adverse outcome affecting pregnancy [51].  
 
The term ‘gestational diabetes’ potentially includes two different cohorts of women; those 
who already have T2DM or impaired glucose tolerance or impaired fasting glucose or both, 
but who have not had any previous clinical symptoms or signs leading to diagnosis and those 
who develop glucose intolerance during the course of pregnancy. These two cohorts will 
likely be impacted by hyperglycemia in different ways. Hyperglycemia throughout the first-
trimester increases the risk of a teratogenic effect during embryogenesis and may lead to 
worse pregnancy outcomes, although there are little data to support this or early treatment 
[52,53]. The IADPSG does, however, suggest that women deemed ‘high-risk’ for diabetes 
have an early glucose tolerance test allowing earlier intervention [49]. 
 
Traditional models for risk prediction rely on the binary assessment of maternal demographic 
and medical characteristics [53,54]. These are easy to apply – at any gestation – but are not 
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typically weighted to adequately reflect the relative risk associated with each characteristic. 
In addition, negative findings (for example the lack of GDM in a previous pregnancy) are not 
normally scored during assessment – reducing the specificity of this form of assessment. An 
alternative strategy involves the development of a multivariate algorithm that can weight 
each factor (be it maternal history or a biochemical or biophysical test) appropriately [56-58].  
 
Effective multivariate models have already been developed and validated for first-trimester 
screening for aneuploidy and PE [15,59,60]. Most groups that have developed algorithms for 
GDM have used a similar approach. Risk calculation first involves the assessment of 
maternal demographic and health characteristics that are used to generate an ‘a priori’ risk. 
Other investigative tools can then be measured and findings expressed as likelihood ratios 
that are used to manipulate the background risk and produce an ‘adjusted’ risk. A fixed risk 
‘cut-off’ can then be used to define a cohort of high-risk pregnancies. This process allows 
several investigational findings to be included in risk assessment that can be chosen to best 
represent different etiological pathways associated with the disease. In the case of GDM, 
potentially driven by a reduction in insulin secretion or an increase in insulin resistance, this 
could include assessment of biochemical markers of long-term maternal glycemic control, fat 
and steroid metabolism and systemic inflammation as well as biochemical markers of 
placental function. Biophysical assessment of maternal adiposity and blood pressure may also 
be of value.  
 
First-trimester screening algorithms for aneuploidy and PE include some shared markers of 
placental function and maternal wellbeing and, to maximize cost effectiveness and ease of 
screening, it would be useful to complete prediction of GDM at the same time point. This 
would also maximize opportunity for early diagnosis and treatment of occult T2DM as well 
as provide an opportunity to apply preventative interventions aiming to reduce the population 
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prevalence of GDM. The multivariate algorithms of Nanda et al. and Syngelaki et al. (both 
from the FMF) have shown that applying a computerized risk scoring algorithm improves 
screening efficacy by maternal history and that addition of currently available screening 
markers (PAPP-A and PLGF; used for aneuploidy and PE) is of little added advantage 
[56,61,62]. In contrast, Sweeting et al. found that inclusion of PAPP-A in the algorithm did 
improve screening efficacy, although other commonly used first trimester markers were of 
little added value [63]. Interestingly, PAPP-A was more widely displaced in South Asian 
rather than Caucasian women – raising the possibility that different markers may be of use in 
different settings. Syngelaki et al. also found that inflammatory markers (hs-CRP and TNFα) 
were of limited added value (improving sensitivity by 1%) [64]. Adiponectin and sex 
hormone binding globulin are both reduced in pregnancies that continue to develop GDM and 
these markers improve screening sensitivity by 6% compared to maternal history alone [61]. 
Interestingly, Syngelaki et al. made these comparisons at a fixed screen positive rate of 90%; 
given the fact that >15% of women can be expected to develop GDM, a higher screen 
positive threshold would be more useful. Farina et al. also used this fixed risk cut-off when 
developing a model using both adiponectin and PAPP-A – with 72% sensitivity [65]. The 
adiponectin association was further validated by two other groups [66,67]; in one of the 
studies, assessment at a fixed screen positive rate of 25% gave 80% sensitivity [67]. Whilst  
fasting plasma glucose is associated with GDM, this is a difficult test to include in a one-stop 
screening clinic that may give appointments late in the day [68]. Glycosylation and/or 
glycation of proteins such as fibronectin and CD59 (respectively) have recently been shown 
to have high ROC AUC scores and further work is needed to see if these can be combined 
with other maternal characteristics and investigational tools [69,70]. 
 
Whilst first-trimester prediction of early onset PE has been shown to be an effective means of 
identifying high-risk pregnancies for preventative intervention [71], no such studies currently 
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exist for first-trimester prediction and prevention of GDM. Potential preventative 
interventions that could be tested once an effective screening algorithm is defined and 
validated include early dietary intervention, use of probiotics and oral hypoglycemic agents 
such as metformin [71-73]. We anticipate this work will continue and bear a fruitful outcome 
within the next five years. 
 
  
(4) Later health of mother and child  
Gestational diabetes and later maternal health 
GDM is well recognized as a risk marker for future (generally Type 2) diabetes in parous 
women [74]. Varying definitions and protocols for detection of GDM and the potentially 
confounding effect of treatment during pregnancy have made comparisons of the risks across 
various countries difficult in the past.  However, the recently presented results of the HAPO 
follow up study, involving a multinational, blinded and untreated cohort of almost 4700 
demonstrated that IADPSG / WHO defined GDM was associated with a 10.7% risk of T2DM 
and a 52.2% risk of abnormal glucose metabolism at 11 years post-partum – clearly a 
substantial risk.  Beyond the risk of diabetes, elevated risks of hypertension, dyslipidemia and 
pre-clinical cardiovascular disease also pose threats to long-term maternal health. 
Despite these risks, the potential for diabetes prevention in this group of women is often 
characterized as a lost opportunity.  Rates of glycemic testing post-partum remain poor in 
most parts of the world, with variable motivation, dominant concern for the infant’s health, 
lack of knowledge on the part of health care providers, difficulty maintaining long-term 
lifestyle changes and lack of systematic follow up frequently cited as practical barriers to 
optimal detection of impaired glucose metabolism [75].  
Observational studies confirm that women who increase their physical activity in the post-
partum period do fare better in terms of weight control, but such changes are difficult to 
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maintain and efficacy in terms of reduced progression to diabetes has been more difficult to 
demonstrate.  Results in randomized studies have frequently been negative [76].  Perez-Ferre 
N et al. reported success in reducing progression to abnormal glucose metabolism by 25% 
over 3 years post-partum using a Mediterranean diet and a medically supervised lifestyle 
intervention aimed at increasing physical activity to 150 minutes / week [77]. 
Results from the United States based Diabetes Prevention Program (DPP), reported by Aroda 
et al. demonstrated that women with prior GDM had higher rates of progression to T2DM 
(11.4 cases / 100 person-years) than parous women without a GDM history (6.9) [78].  
Furthermore, these women developed impaired glucose tolerance at a younger age and 
responded better to metformin as a preventative treatment.  However, the mean age of post 
GDM women at the time of recruitment into the DPP was 43 years, casting doubt as to the 
relevance of these findings to early post-partum care. In terms of pharmacological 
intervention, Buchanan et al. have also demonstrated efficacy in prevention of progression 
towards diabetes in high risk women using troglitazone (now withdrawn due to 
hepatotoxicity) and pioglitazone [79,80].  This provides some “proof of principle” that 
substantial reduction in insulin resistance may delay the onset of overt diabetes post GDM, 
but implementation awaits the development of agents with a satisfactory risk profile. 
Promotion of breast-feeding carries great potential as a means of promotion both mother and 
baby health post GDM.  Though RCT evidence in this area is not feasible, the SWIFT cohort 
study provides clear epidemiologic support for reduced progression to DM with increased 
duration and intensity of lactation following a GDM pregnancy [81].  
 
GDM and later infant health 
In addition to the future risk of diabetes and other metabolic complications for the mother, in 
utero exposure of the developing fetus to the hyperglycemic environment of maternal GDM 
also carries long-term risks for the baby of impaired glucose metabolism and obesity, though 
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the relative importance of maternal hyperglycemia, maternal obesity and exposures during 
childhood as antecedents of these infant effects are still not entirely clear [82-87].  
 
Unfortunately, we currently have no convincing evidence that existing protocols for 
diagnosis and treatment of GDM reduce later risks for the infant.  A follow up study at Age 4 
– 5 years of children born to mothers in the ACHOIS randomized trial showed no benefit of 
treatment in reducing childhood BMI [88].  A more detailed follow up at Age 5 – 10 years of 
children born to mothers in the United States MFMNU randomized trial also showed no 
overall benefit of treatment of maternal GDM in terms of body mass index and other markers 
of glucose and lipid metabolism [89].  However, the authors did note a gender difference, 
with lower fasting glucose observed in female offspring of mothers treated for GDM.   
 
There are many potential explanations for this apparent lack of benefit from current therapy.  
Sovio et al. have demonstrated that excess fetal growth in utero is evident by 20 weeks’ 
gestation, prior to the conventional time of GDM diagnosis [90].  Hernandez et al. have 
reviewed studies of glucose patterns in pregnancy in normal women and note that current 
glycemic targets recommended for GDM therapy lie well above the ranges experienced in 
normal pregnancy [91].  Thus, our current therapy may be “too little” and / or “too late”.  
Further research with long term infant follow up is required to resolve this therapeutic 
dilemma.  
 
Preeclampsia and later maternal health 
Diagnosis of PE also carries long-term health risks for mother and infant.  For the mother, the 
risk of later cardiovascular disease were identified by Epstein in 1964 and include long term 
chronic hypertension, T2DM and metabolic syndrome [92-95].  A recent review by Berks et 
al. has further suggested that post-partum interventions may reduce long-term risks for 
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women with PE [96].  The American Heart Association and ACOG now recommend lifestyle 
assessment and intervention in women with prior PE with the aim of reducing long-term risks 
[97]. 
 
Preeclampsia and later infant health 
Maternal PE also carries risks for the offspring.  In the long-term, stroke risk at Age 65 
appears elevated, though coronary artery disease was not increased [98].  Metabolic 
consequences such as obesity, insulin resistance and increased vascular inflammatory 
markers have also been noted at younger ages and animal studies suggest possible causal 
links [99].   
 
Thus, both HIP / GDM and PE provide windows into future health risk prediction for mother 
and infant and deserve close clinical attention and diligent follow up.  
 
Conclusions 
The global community is beginning to understand the enormity of the health and economic 
challenges presented by NCDs.  
 
By 2030, NCDs are projected to claim 52 million lives annually. Almost 80% of these deaths 
will occur prematurely in low- or low/middle-income countries. Worldwide, obesity has 
nearly doubled since 1980. In 2008, 35% adults aged >20 years (>1.4 billion) were 
overweight; of these, 11% were obese (200 million men and nearly 300 million women). 
Over a billion people live with high blood pressure. In 2008, the global prevalence of high 
blood pressure in adults aged >25 years was around 40%. Over 700 million people have 
dysglycemia (diabetes mellitus, impaired glucose tolerance or impaired fasting glucose).  
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Systematic testing during pregnancy and especially during the first-trimester, offers a 
window of opportunity to provide enhanced maternal care services and reduce adverse 
intrauterine exposures throughout pregnancy. Such an approach offers the opportunity not 
only to reduce the traditionally recognized short-term maternal and perinatal morbidity and 
mortality indicators but also for intergenerational prevention of future chronic diseases for 
both mother and offspring.  
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